This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
For ReFacto AF® (moroctocog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.
When monitoring patients' factor VIII activity levels during treatment with ReFacto AF®, the use of a chromogenic substrate assay is recommended. Typically, the chromogenic assay yields results that are higher than those observed with use of the one-stage clotting assay.1
The ReFacto AF® Laboratory Standard was created for use with the one-stage clotting assay (or the chromogenic assay), when testing plasma samples from patients receiving ReFacto AF®.1 It can be used exactly as you would use a normal (plasma-based) laboratory standard.2
There are 3 steps involved in preparing the ReFacto AF® Laboratory Standard.
Step 1
The Refacto AF Laboratory Standard is intended as a calibrated reference in constructing standard or calibration curves for one-stage clotting or chromogenic substrate coagulation assays.3
For more information, please refer to the Laboratory Standard leaflet in the support and resources page or get in touch with the Pfizer Haemophilia team here.
Access data on the clinical efficacy & safety of ReFacto AF® for prophylaxis, on-demand treatment, and surgery.
Access resources and additional information that aim to support you and your patients.
Contact us for more information on ReFacto AF and download our FAQ for supply and stock related queries.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021